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Background: The TNFAIP3 gene, which encodes a ubiquitin-modifying enzyme (A20) involved in the negative
regulation of NF-κB signaling, is frequently inactivated by gene deletions/mutations in a variety of B-cell
malignancies. However, the detection of this in primary Hodgkin lymphoma (HL) specimens is hampered by the
scarcity of Hodgkin Reed-Sternberg (HR-S) cells even after enrichment by micro-dissection.
Methods: We used anti-CD30 immunofluorescence with fluorescence in-situ hybridization (FISH) to evaluate the
relative number of TNFAIP3/CEP6 double-positive signals in CD30-positive cells.
Results: From a total of 47 primary classical Hodgkin lymphoma (cHL) specimens, 44 were evaluable. We found
that the relative numbers of TNFAIP3/CD30 cells were distributed among three groups, corresponding to those
having homozygous (11%), heterozygous (32%), and no (57%) deletions in TNFAIP3. This shows that TNFAIP3
deletions could be sensitively detected using our chosen methods.
Conclusions: Comparing the results with mutation analysis, TNFAIP3 inactivation was shown to have escaped
detection in many samples with homozygous deletions. This suggests that TNFAIP3 inactivation in primary cHL
specimens might be more frequent than previously reported.
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The TNFAIP3/A20 gene encodes a ubiquitin-modifying
enzyme involved in the termination of NF-κB responses,
so is a negative regulator of NF-κB signaling [1,2].
TNFAIP3 is located on chromosome 6q23, and deletion
of one allele has been detected in Hodgkin lymphoma
(HL) and other B-cell malignancies [3-9].
We previously showed that TNFAIP3 is a common
genetic target in B-cell lymphomas, following an analysis
of 265 samples obtained from various B-cell lymphomas
using either comparative genomic hybridization (CGH)
or TNFAIP3 mutation analysis. We observed TNFAIP3
mutations and/or deletions in 31 cases [3]. This previous
work also included samples from 24 primary classic HL
(cHL) cases, and we performed mutation analysis of
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reproduction in any medium, provided the or(HR-S) cells. This revealed one intronic and four
missense mutations, indicating the existence of cHL het-
erogeneity. However, it is conceivable that we did not de-
tect homozygous deletions, which have been shown in
other B-cell lymphoma subtypes and HL cell lines, and
that we underestimated the frequency of involvement of
TNFAIP3 in primary cHL cases.
In order to accurately evaluate the frequency of in-
volvement of TNFAIP3 in cHL, we performed Fzluores-
cence Immunophenotyping and interphase Cytogenetics
as a Tool for the Investigation Of Neoplasm (FICTION)
[10] to examine TNFAIP3 deletions in cHL. A total of 47
cHL cases were examined for the presence or absence of
TNFAIP3 deletions, including 22 of 24 cases with se-
quence data previously reported.
Methods
Samples
The study consisted of 47 cHL biopsy specimens, including
30 from our previous cohort archived in the Nationall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and 17 obtained from The Cancer Institute Hospital of the
Japanese Foundation For Cancer Research. This research
was carried out in compliance with the Helsinki Declar-
ation, and was approved by the Institutional Review Board
at the NCC (20–010).
Twenty-two of the 47 cases had been examined previ-
ously by sequence analysis, and four found to have mis-
sense mutations. In addition, we examined the sequence
of six cases in the present study. Specimens were fixed
in formalin or methanol and embedded in paraffin, then
cut into thin sections and laid on a glass slide. One sec-
tion of each specimen was subjected to FICTION ana-
lysis and the other to sequence analysis.
FICTION analysis
Approximately 4-μm-thick sections were immunostained
with an anti-CD30 antibody to identify HR-S cells. The
CD30 antibody (BerH2) (Dako, Glostrup, Denmark) was
diluted 100-fold and incubated overnight at 4°C. The
fluorescence labeled antibodies Alexafluor 647 Rabbit
Anti-mouse IgG, Alexafluor 647 Goat Anti-rabbit IgG and
Alexafluor 647 Donkey Anti-goat IgG, were used as the
secondary, tertiary, and quaternary antibodies, respectively
(Molecular Probes, Life Technologies Corporation, Foster
City, CA). Each of these antibodies was diluted 1000-fold
and incubated for 30 min at room temperature (RT).
A BAC clone library was screened to identify a clone
suitable for the fluorescence in-situ hybridization (FISH)
analysis of TNFAIP3. Clone RP11-783B20 (TNFAIP3
locus, 6q23) was selected based on the best signal/noise
ratio upon hybridization to the normal karyotype (Abbot
Laboratories, Abbot, IL). RP11-783B20 was labeled with
spectrum orange by nick translation (Abbot Laboratories)
according to the manufacturer’s instructions. The CEP6
Spectrum Green Probe (Abbot Laboratories) was used to
detect the centromere of chromosome 6 (6p11.1-q11) as a
reference. Double-color FISH was performed using the
Histology FISH Accessory kit (Dako). The hybridization
mixture consisted of 2 μl of the TNFAIP3 probe, 2 μl of
the 1/20-diluted CEP 6 probe, 1 μl of Cot1-DNA, and 5 μl
of 20% dextran sulfate/4 × SSC. After denaturation at 76°C
for 6 min, the solutions were laid onto a glass slide and
incubated overnight at 37°C for hybridization according to
the manufacturer’s instructions. Nuclear staining was per-
formed with DAPI. We visualized the sections under a
four-color fluorescence microscope, BIOREVO (Keyence
Corporation, Osaka, Japan).
Statistical analysis
As the diameter of HR-S cells is several-fold greater than
the 4 μm thickness of the FISH sections, the TNFAIP3/
CEP6 signal ratio was calculated to evaluate the
TNFAIP3 status in CD30-positive cells. The signal ratiowas also calculated in the surrounding normal CD30-
negative cells, which were used as a control. We counted
the signal ratio for 30 CD30-positive cells and 50 CD30-
negative cells. Only CD30-positive cells of large morph-
ology were regarded as HL cells.
The cutoff level to estimate gene deletion(s) was deter-
mined by calculating the ratio of the TNFAIP3/CEP6
signal in the subject cells to that in the normal control
cells in samples showing obvious deletions from se-
quence analysis. P-values < 0.05 were considered statisti-
cally significant.
Results
In total, specimens from 47 patients were analyzed
(Table 1). The predominant type of cHL was nodular scler-
osis (NS, n=28), followed by mixed cellularity (n=14),
lymphocyte-depletion (LD, n= 2), and lymphocyte-rich
(LR, n=3). Of the 47 patients, 19 were male and 28 were
female. Disease stages I, II, III and IV were evident in eight,
24, 10 and five cases, respectively. B symptoms were
present in 12 cases and absent in the remaining 35 cases.
In all, 15 cases tested positive for EBV and the remaining
32 showed a negative result.
The signals were successfully detected in all cases
(Figure 1A-D). The mean numbers of TNFAIP3 signals
and CEP6 signals per CD30-negative cell were almost
the same in most cases, except for cases #40, 42 and
45, where the number of TNFAIP3 signals was mark-
edly lower than that of CEP6 signals, with ratios of
0.86, 0.89 and 0.84, respectively. These cases were
excluded from further analysis as the number of avail-
able slides was limited and the analysis could not be
repeated more than twice. In all remaining cases, the
TNFAIP3/CEP6 signal ratio in CD30-negative cells was
approximately 1.0.
The mean number of CEP6 signals in CD30-positive
cells was 1.2 ± 0.3, which was less than that of CD30-
negative cells (1.5 ± 0.1). In addition, the mean number
of TNFAIP3 signals per CD30-positive cell was less than
that of CEP6; the mean number of TNFAIP3: CEP6 sig-
nals per CD30-positive cell was 0.60, significantly lower
than that in control CD30-negative cells (p < 0.001). The
relative numbers of signals determined by FICTION
analysis in the 47 cases are shown in Table 2.
The TNFAIP3/CEP6 signal ratio in CD30-positive
cells was divided by that in CD30-negative cells to give
the relative TNFAIP3/CEP6 signal ratio; further ana-
lysis was then performed to determine whether
TNFAIP3 deletions existed in CD30-positive cells. The
relative TNFAIP3/CEP6 signal ratio was distributed
into three peaks. Construction of a histogram based
on 0.05 increments revealed no cases with relative
ratios of 0.25–0.30 or those of 0.55–0.60, which sepa-
rated the three distribution peaks. We contended that
Table 1 Patient characteristics
Case # Diagnosis Age (years) Gender Stage B symptom EBER-1
1 NS 28 F II - -
2 NS 44 F II - +
3 NS 30 M I - -
4 NS 27 F II - -
5 NS 18 F II - -
6 NS 27 M II + -
7 NS 22 M IV - -
8 NS 57 M III - -
9 NS 48 M III -
10 MC 29 M IV - -
11 NS 34 M II - -
12 NS 22 F II - -
13 NS 14 F I - -
14 MC 53 M I - -
15 MC 59 M I - +
16 MC 42 M III + -
17 MC 50 M II - -
18 MC 29 F II + +
19 MC 50 M I - +
20 NS 39 F IV - -
21 NS 22 F II + -
22 MC 55 F I - +
23 LD 59 F I - -
24 NS 32 F II + -
25 NS 16 M III - -
26 NS 24 F III - -
27 NS 20 M II - -
28 MC 67 F IV + +
29 NS 26 F II - -
30 MC 73 F IV - +
31 MC 74 F II - -
32 LR 81 F II - -
33 MC 75 F III + +
34 MC 33 F III + -
35 MC 62 F III - +
36 MC 53 M II - +
37 LR 72 M II - +
38 NS 16 F II - -
39 NS 36 F II + -
40 NS 16 F II - -
41 LR 48 M III + +
42 LD 67 M I - +
43 NS 27 F II - -
44 NS 43 F II - -
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Table 1 Patient characteristics (Continued)
45 NS 64 M II + -
46 NS 66 F III - +
47 NS 24 F II - +
NS, Nodular sclerosis cHL; MC, Mixed cellularity cHL; LD, Lymphocyte-depleted cHL; LR, lymphocyte-rich cHL.
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tion status. The first peak, corresponding to the lowest
relative ratios, was considered to represent cases with
homozygous deletions; the second peak, corresponding to
intermediate ratios, represented cases with heterozygous
deletions; and the third peak, corresponding to the highest
relative ratios, represented cases with no deletions. Two
cutoff levels were thus determined (0.25 and 0.55), distin-
guishing between cases with homozygous deletions and
heterozygous deletions, and between cases with heterozy-
gous and no deletions, respectively.
Using these two cutoff levels, we determined that five
of the 44 cases had homozygous deletions and 14 cases
had heterozygous deletions. The relative TNFAIP3/CEP6
signal ratios in the former cases (#6, 12, 21, 26, and 41)
were 0.13, 0.21, 0.22, 0.14, and 0.21, respectively, sug-
gestive of almost complete loss of TNFAIP3. In two of
these cases (#6, and #41), sequence analysis had previ-
ously been performed [3], and only wild type sequence
had been shown. Fourteen cases were assumed to have
heterozygous deletions, of which nine had previously
undergone sequence analysis revealing no mutations.Figure 1 Results of FICTION analysis. FICTION assay combining CD30-
chromosome 6 centromere (green). White arrows indicate CD30-positive
deletion. (D) Homozygous deletion (×1,000).The remaining 25 cases were assumed to have no dele-
tions, of which 14 had previous sequence data showing
three cases (#3, #38, and #46) with gene mutations. The
sequencing analysis revealed no residual wild-type
TNFAIP3. In these cases, the relative TNFAIP3/CEP6
signal ratio was 0.72, 0.69, and 0.70, respectively.
We next carried out statistical analysis of the relationship
between TNFAIP3 deletions as detected by FICTION ana-
lysis and clinical data. The frequency of TNFAIP3 deletions
was higher in cases with B symptoms, although the differ-
ence was not statistically significant (p=0.11) (Table 3).
There were no significant differences related to the patient
gender, cHL type, or the disease stage. Cases with mutated
TNFAIP3 were then combined with those with deletions,
again revealing no statistically significant correlations with
clinic pathological characteristics (data not shown).
The frequency of deletions was not significantly dif-
ferent between cases with and without evidence of
EBV infection. However, all NS type cases with homo-
zygous TNFAIP3 deletions were found to be negative
for EBV; among the remaining 40 cases, 13 tested posi-
tive for EBV.expressing cells (yellow) and FISH probes for A20 (red) and
cells. (A) Low-power field (×300). (B) Normal cells. (C) Heterozygous
Table 2 FICTION analysis








1 W 1.02 0.90 0.88 2
2 W 0.98 0.63 0.64 2
3 1487C>A
(T474N)
0.99 0.71 0.72 2
4 W 1.11 0.80 0.72 2
5 W 1.11 0.54 0.49 1
6 W 1.06 0.14 0.13 0
7 W 0.94 0.65 0.69 2
8 W 0.96 0.45 0.47 1
9 W 1.01 0.64 0.63 2
10 W 0.97 0.77 0.79 2
11 W 1.02 0.81 0.79 2
12 ND 1.03 0.22 0.21 0
13 ND 0.99 0.93 0.94 2
14 ND 1.12 0.78 0.70 2
15 ND 1.04 0.83 0.80 2
16 ND 1.05 0.42 0.40 1
17 ND 1.19 1.07 0.90 2
18 ND 1.00 0.67 0.67 2
19 ND 1.17 0.50 0.43 1
20 ND 0.99 0.90 0.91 2
21 ND 0.95 0.21 0.22 0
22 ND 0.97 0.68 0.70 2
23 ND 0.93 0.71 0.76 2
24 ND 0.99 0.70 0.71 2
25 ND 1.00 0.82 0.82 2
26 ND 1.00 0.14 0.14 0
27 ND 1.02 0.32 0.31 1
28 ND 0.99 0.50 0.51 1
29 ND 0.99 0.41 0.41 1
30 ND 0.97 0.76 0.78 2
31 W 1.03 0.45 0.44 1
32 W 1.01 0.88 0.86 2
33 W 0.97 0.52 0.53 1
34 W 0.99 0.52 0.52 1
35 W 1.00 0.93 0.93 2
36 W 0.90 0.63 0.71 2
37 W 0.98 0.43 0.44 1
38 1777G>A
(V571I)
1.04 0.72 0.69 2
39 W 1.06 1.00 0.94 2
40 1156A>G
(R364G)
0.86 0.15 0.17 ND
41 W 0.91 0.19 0.21 0
42 W 0.89 0.31 0.35 ND
Table 2 FICTION analysis (Continued)
43 W 1.00 0.36 0.36 1
44 W 1.01 0.52 0.51 1
45 W 0.84 0.68 0.81 ND
46 569G>A
(STOP)
0.99 0.69 0.70 2
47 W 1.00 0.45 0.45 1
3/25 (12%) Mean 1.01 Mean 0.61 Mean 0.60
* 0: homozygous, 5 cases; 1: heterozygous, 14 cases; 2: non deleted, 25 cases.
W, wild type; ND, not determined.
Cases #1-5 and #31-47 had been sequenced and reported elsewhere. Cases
#6-11 were sequenced in this study. Cases #12-30 were not sequenced
because of limited or poor quality DNA.
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FICTION analysis is useful to detect gain-of-function
gene deletions in certain cells [4], and was used in the
present study to evaluate the frequency of TNFAIP3
deletions in cHL. In FISH analysis, use of thinner sec-
tions enables improved probe penetration and better sig-
nal visualization. However, as the average HR-S cell is
30–50 μm in diameter, this far exceeds the maximum
FISH section thickness of 4 μm, so evaluation of signal
number is difficult. We conducted the analysis in a large
number of cells, calculated the TNFAIP3/CEP6 signal
ratio and determined the cutoff level, which contributed
to the determination of allele frequency at the TNFAIP3
locus in cHL cases.
Of the 44 evaluable cases, 19 had deletions, which is con-
sistent with the frequency reported in a previous deletion
study (9/21) [7], confirming that TNFAIP3 is frequently lost
in malignant cells in cHL. Five cases had homozygous dele-
tions and two of these had a normal sequence, possibly be-
cause of contamination from surrounding cells which
cannot be avoided during microdissection. Thus, homozy-
gous deletions might be missed in sequence analysis of HR-
S cells. For this reason, our previous study only includedTable 3 Univariate analysis





NS 14 12 0.63
Others 11 8
I - II 17 12 0.74
III - IV 8 7
B + 4 7 0.11
B - 21 12
EBV + 8 6 0.98
EBV - 17 13
M 10 7 0.83
F 15 12
NS, Nodular sclerosis cHL; M, male; F, female.
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with homozygous deletions might also have been excluded
because of unsuccessful PCR amplification, irrespective of
DNA quality. If these cases had been included, the fre-
quency of TNFAIP3 homozygous deletions might be much
higher than previously thought.
The allele status of case #40 could not be determined
because of the limited sample number; however, this
case had a very low TNFAIP3/CEP6 signal ratio. A pre-
vious sequence analysis of the same case revealed both
mutated and wild-type alleles. If it is assumed that the
HR-S cells were diploid, the results could be sorted into
homozygous, heterozygous, and no deletions. However,
karyotype analysis previously demonstrated the cells to
be triploid or tetraploid in some cases [11]. Therefore,
it is possible that the mutated allele co-exists with two
or three wild-type alleles in triploidy or tetraploidy, re-
spectively. Alternatively, this could be explained by
tumor cell heterogeneity in which HR-S is a mixture of
cells with a mutated gene and cells with deleted genes.
Of the 14 cases identified to have heterozygous dele-
tions, sequence analysis data were available for nine but
no mutations were detected in any of these cases. This
could be a result of the gene repression caused by pro-
moter methylation, which was shown for MALT lymph-
oma by Chanudet et al. [7]. In cases of MALT and other
lymphomas, TNFAIP3 has been postulated to work as a
tumor-suppressor gene. However, it has been difficult to
determine allele loss in cHL cases because CGH analysis
is laborious and requires large numbers of micro-
dissected cells [12]. FICTION was used in the present
study to overcome this limitation.
In the 25 cases thought to have no TNFAIP3 loss, se-
quence data were available for 14 of which three showed
TNFAIP3 mutations and the chromatogram did not
show the remaining wild-type allele. This result is com-
patible with that of previous allele-specific CGH analysis,
which showed a significant number of B-cell lymphoma
cases with uniparental disomy (UPD) [3]. Of the three
cases with TNFAIP3 mutations in the present study, loss
of function was caused by UPD. However, for the
remaining 11 cases in which both FICTION and se-
quence data were available, no TNFAIP3 deletion was
again noted.
We found that B symptoms were more frequent in
cases with TNFAIP3 deletions, although the difference
was not statistically significant. Knockout experiments
have suggested that TNFAIP3 plays a role in the termin-
ation of inflammation [13]. As B symptoms represent the
inflammatory process, we speculated that absence of
TNFAIP3 causes termination of the inflammatory
process to fail, resulting in continuous activation of NF-
κB signaling and classical Pel-Ebstein fever in cHL
patients. However, to confirm this, further expressionstudies of the TNFAIP3 gene product in more cases are
required.
All five cases with TNFAIP3 homozygous deletions in the
present study were EBV-negative, as were four of the 14
cases of heterozygous deletion. Schmitz et al. previously
found that the frequency of TNFAIP3 mutations in EBV-
negative cases was significantly higher than in EBV-positive
cases [7]. As our study included fewer EBV-positive cases,
we could not confirm this report and further study includ-
ing methylation analysis of TNFAIP3 will be necessary.
Conclusion
Homozygous deletion of TNFAIP3 in cHL cases might be
more frequent than previously thought. Homozygous
deletions were found in 11% of our cases, and our findings
strongly suggest that TNFAIP3 serves as a tumor-
suppressor gene in cHL. Screening for TNFAIP3 by FIC-
TION analysis is a useful, cost-effective and rapid research
tool to identify heterogeneity among cHL cases.
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